Gates Biomanufacturing Facility announces manufacture of recombinant protein – Alzheimer’s disease vaccine for Institute for Molecular Medicine’s clinical trials
The Gates Biomanufacturing Facility (GBF) has announced the successful completion of the full cycle manufacturing of the recombinant Bulk Drug Substance (BDS) of the anti-Tau...
















